About Kernal Biologics, Inc. Kernal Bio is a venture-backed therapeutics company engineering cells inside the body using AI-designed, selective mRNA and targeted LNP technology. By developing in vivo CAR-T therapies, Kernal Bio is advancing precision treatments for autoimmune diseases and blood cancers. The company was founded by experts from MIT, Harvard, Merck, and BMS, and its leadership team brings a track record of three FDA-approved therapi...
Kernal Bio is a venture-backed therapeutics company engineering cells inside the body using AI-designed, selective mRNA and targeted LNP technology. By developing in vivo CAR-T therapies, Kernal Bio is advancing precision treatments for autoimmune diseases and blood cancers. The company was founded by experts from MIT, Harvard, Merck, and BMS, and its leadership team brings a track record of three FDA-approved therapies and over 120 patents. With...
At Kernal Bio, we engineer human cells inside the body using selective mRNA-LNP technology to treat cancer and autoimmune diseases. Our AI-designed mRNAs, delivered via antibody-decorated lipid nanoparticles (LNPs), ensure precise targeting and minimize off-target effects. Our KR-402 program focuses on hematological malignancies and autoimmune disorders, achieving >90% in vivo delivery efficiency with T-cell-targeted LNPs. The KR-335 program, tar...
September 24, 2025. Position. . Senior Computational Biologist/ ML Scientist. Company Overview. . At Kernal Bio, we engineer human cells inside the body using selective mRNA-LNP technology to treat cancer and autoimmune diseases. Our AI-designed mRNAs, delivered via antibody-decorated lipid nanoparticles (LNPs), ensure precise targeting and minimize off-target effects. Our KR-402 program focuses on hematological malignancies and autoimmune di...
Scientist I/II: in vivo Pharmacology / Immuno-Oncology. At Kernal Bio, we engineer human cells inside the body using selective mRNA-LNP technology to treat cancer and autoimmune diseases. Our AI-designed mRNAs, delivered via antibody-decorated lipid nanoparticles (LNPs), ensure precise targeting and minimize off-target effects. Our KR-402 program focuses on hematological malignancies and autoimmune disorders, achieving >90% in vivo delivery effic...
